Targeting a signaling pathway activated by acidic tumor environment restores treatment response to PARP inhibitors in ovarian cancer
PARP inhibitors are among the most widely used therapies for ovarian cancer, but their long-term effectiveness is limited by acquired resistance Researchers ...
